Press releases
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
- Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
- Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
More ▼
Key statistics
As of last trade Organon & Co (7XP:DUS) traded at 17.24, -22.45% below its 52-week high of 22.23, set on May 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.02 |
---|---|
High | 17.24 |
Low | 17.02 |
Bid | 17.24 |
Offer | 17.37 |
Previous close | 16.93 |
Average volume | 429.89 |
---|---|
Shares outstanding | 255.64m |
Free float | 255.27m |
P/E (TTM) | 4.62 |
Market cap | 4.71bn USD |
EPS (TTM) | 3.99 USD |
Annual div (ADY) | 1.04 EUR |
---|---|
Annual div yield (ADY) | 6.11% |
Div ex-date | Feb 23 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Apr 26 2024 15:00 BST.
More ▼